National Alliance Biosimilars Placemat

Biosimilars are the future of specialty drug therapy, costing, on average, 50% less than their biological reference products, with some exceeding 90%. While adoption has been hindered by barriers such as questionable pharmacy benefit manager (PBM) formulary decisions and patient/prescriber hesitancy, employers/purchasers can set vendor expectations and provide education to accelerate uptake. Doing so leads to better management of the soaring cost of biologic medicines, which account for 46% of pharmaceutical spending—but only 2% of all prescriptions. View the companion toolkit.